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Research coordinatorResearch, clinical care, and education are the three cornerstones of academic health centers in the United States.
The research climate has always been riddled with ebbs and ﬂows, depending on funding availability. During a
time of reduced funding, the number and scope of research studies have been reduced, and in some instances,
a ﬁeld of study has been eliminated. Recent reductions in the research funding landscape have led institutions
to explore new ways to continue supporting research. Mayo Clinic in Rochester, MN has developed a clinical
trial unit within the Department of Medicine, which provides shared resources for many researchers and serves
as a solution for training andmentoring new investigators and study teams. By building on existing infrastructure
and providing supplemental resources to existing research, the Department of Medicine clinical trial unit
has evolved into an effective mechanism for conducting research. This article discusses the creation of a central
unit to provide research support in clinical trials and presents the advantages, disadvantages, and required
building blocks for such a unit.
© 2015 Mayo Clinic. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Research is deﬁned as “the systematic investigation into and study of
materials and sources in order to establish facts and reach new conclu-
sions.” Good Clinical Practice (GCP) is the basis for quality and human
subject safety in all clinical research and provides guidance that must
be strictly adhered to before, during, and after a research study is under-
taken [1]. Unfortunately to quote Eisenberg, et al. “…over time, clinical
trials in the United States have become too expensive, difﬁcult to enroll,
inefﬁcient to implement, and ineffective to support the development
of new medical products using modern evidentiary standards” [2].
This has been especially true in the current climate where funding has
been reduced or completely eliminated for some research ﬁelds of study.
Clinicians are in a unique position to conduct patient-centered re-
search and health care delivery improvements. Although physiciansCenters; CRO, Clinical Research
; CTU, clinical trial unit; DOM,
istration; GCP, Good Clinical
orting Center; NIH, National
oordinators.




. This is an open access article underare adroit at identifying clinical questions, very few of these ideas ulti-
mately result in research projects. The challenge in translating ideas to
projects is due, in large part, to a lack of investigator research knowledge
and an inability to execute research ideas, as well as unfamiliarity with
the research landscape and its numerous regulations. In addition, physi-
cians are hampered by the lack of time and competing demands. A re-
view of investigators that received warning letters from the Food Drug
Administration (FDA) as a result of site audits, found that failure of a
principal investigator (PI) to supervise trials was the leading cause for
the warning letters [3] (N37% of PIs audited in 2001 vs. 19% of PIs
audited in 2000). [4]; other reasons cited included the coordinator's fail-
ure to complete all study duties, such as IRB submissions. All of these el-
ements present critical barriers to conducting high quality research,
which can contribute greatly to the advancement of the science and de-
livery of health care.
In an effort to continuously improve clinical trials administration
and better serve patients, the Association of Academic Health Centers
(AAHC) conducted a survey of its member institutions to gauge the na-
ture and scope of clinical trials operations [5]. The results highlight the
challenges facing academic institutions who wish to continue partici-
pating in rapidly evolving research practices. The greatest barrier for
these institutions is the lack of systems and procedures and the sub-
optimization of resources [5].
Clinical researchers who have access to a supporting research infra-
structure are able to increase their knowledge development, improvethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ical practice. The rapidly evolving clinical landscape consists of many
complex and interdependent functions that are often isolated and lack
integration within an institution. There is a great need for value-added
resource(s) to provide expertise for complex trials; offer more over-
sight/guidance and in assistance in partnership with investigators,
and to provide knowledge of study design, initiation, conduct, and
outcomes.
2. Methods
Clinical trials units (CTUs) are specialized biomedical research units
that can help to design and centrally coordinate clinical trials. Much like
a core facility, CTUs can be “centralized shared resources that provide
access to instruments, technologies, services and expert consultation
to scientiﬁc investigators…” [6]. During a period in academia when cli-
nician time and research funding are at a premium, a central CTU can be
established with the purpose of providing assistance in the develop-
ment, application, and implementation of industry- and investigator-
sponsored clinical trials in compliance with Good Clinical Practice
(GCP) and other ethics guidelines. The goal of the CTU is to provide
resources and services to advance research and inform the clinical prac-
tice. This could be accomplished by having the CTU provide a focal point
for clinical trials compliance or educational activities, standardize insti-
tutional policies, address clinical trials billing, or improve ﬁnancial man-
agement of clinical trials.
This approach could be cost-effective because it allows for the shar-
ing of knowledge and expensive resources within an institution. As in
clinical practice, where the care model is moving toward a team-based
“clinical care team,” a centrally-located CTU could act as a “research
team.” This infrastructure could provide scientiﬁc mentorship, protocol
development, and study coordination services. Following the team-
based model, stakeholders with various research skills and knowledge
would collaborate to form a ﬁrst-class research team. The CTU research
team would support research investigators by providing mentorship,
protocol development, regulatory services, and the use of highly-
trained research coordinators; this research team has available institu-
tional resources to manage and complete a research study across the
disciplines and organizational divisions within an institution.
2.1. Building on existing infrastructure
In 2006, in reaction to ﬂuctuations in funding, the Mayo Clinic
Department of Medicine (DOM) undertook an informal process of
“sharing” study coordinators (SCs) in an effort to balance resources. At
the same time, investigators whohad prior success in attaining research
funding, found that the reduced funding resulted in lost resources
to pay for well-trained study coordinators, thereby hampering com-
pletion of the research projects. The “shared-resource” model linked
investigators who had quality trained staff, but no funds with investi-
gators who had funds but lacked quality trained staff. Stafﬁng of SCs
was temporarily shared between the investigators. This model created
a win–win for all involved due to reduced ﬁnancial burden and
increased job stability for the study coordinators. Although this partner-
shipwas successful, the long-term stabilitywas threatened by relentless
changes in the funding landscape. Indeed, even the program funded by
theNational Institutes of Health (NIH) Clinical and Translational Science
Awards (CTSA) have undergone a shift in funding direction in recent
years [7].
In 2009, the DOM provided ﬁnancial resources to develop a Clinical
Research Ofﬁce (CRO). The mission of the CRO was to provide the four
general medical divisions within the DOM with the resources to in-
crease academic productivity. The CRO operated with the “shared-
resource” model. In addition to providing experienced and trained
study coordinators, the CRO provided scientiﬁc mentorship for coordi-
nators and investigators, as well as regulatory guidance statisticalresources and manuscript support to assist investigators in the devel-
opment and implementation of research ideas. Each of the four divi-
sions supported this infrastructure through ﬁnancial contributions
and administrative oversight. First author publications for one of
these four divisions increased from 99 in 2012 to 157 in 2014. The an-
nual participant satisfaction survey indicated that participating investi-
gators were very pleased with the services and requested continued
access to this resource. On the heels of this success, demand for these
services from other areas within the organization greatly increased.
In 2014, the DOM formally expanded services to the remaining nine
DOM divisions (N = 13) through the establishment of the clinical trial
unit (CTU). The CTU was designed to supplement, not replace, existing
research units that served speciﬁc divisions/investigators (including
the DOM CRO as well as other departmental research units). The pur-
pose of this expansion was to fulﬁll a need for service to investigators
who lacked research resources but had funding available. The CTU, un-
like the CRO, is funded through a fee-for-service model. The charge-
back system was designed to offset the operational costs of the unit
and its associated support staff to conduct research studies. Investiga-
tors who access CTU services are billed at an hourly rate based on the
amount and type of work completed. This ﬁnancial model offers a
competitive advantage to investigators, as their study is supported by
highly-trained personnel, for only the hours worked on their speciﬁc
project. The CTU eliminates the need for an investigator to hire, train,
or terminate individuals as their research funding ﬂuctuates. It also
removes the burden from the investigators to pay for back-up support
while the primary coordinator is on vacation, leave, or participating in
continued education for coordinators. The centralization of these func-
tions within the CTU allows investigators to be assigned study staff with
the proper training needed in the study and to begin enrolling patients
faster for competitive enrollment studies. It also eliminates the burden
to the PI for administrative and supervisory oversight for the CTU staff
assigned to him/her for the duration of their study. This effort has resulted
in an overall reduction of personnel expenses for studies.
The fee-for-service approach of the CTU is based on a well-
established process which takes into consideration the average pay
for the individual staff members as well as the overall operating costs
of the CTU. The ﬁnancial goals of the CTU are to recover the costs asso-
ciated with its operation, not to make a proﬁt. Funding is sourced from
internal support rather than external awards (such as Federal, Pharma-
ceutical or Foundation) that are limited due to the current political/
economic climate. Recovering costs and sourcing funds internally
contribute to the strength and long-term sustainability of the program.
2.2. Key elements for optimal clinical trials infrastructure
Research infrastructure provided through a team-based model is
critical to the sustainability and growth of clinical research. The CTU
can operationalize this goal by compiling a “research team” which is
experienced and knowledgeable in interacting with key stakeholders
(Table 1). The success measures that can be derived from the im-
plementation of such a central clinical research unit are deﬁned in
Table 2. While electronic health records, standard nomenclature, and
data standards are critical for efﬁciency in the research environment
[2], these elements alone will not improve or simplify the research pro-
cess for novice investigators. Lack of or limited knowledge and access to
basic research support resources will have a greater impact on research
success than innovation of programs. Fig. 1 presents key resource ele-
ments that should be considered and incorporated into a CTU. Fig. 2
illustrates the basic reporting structure of the CTU in its current state.
3. Results
Within this section, we present three scenarios. The scenarios are
compilations of previously encountered real situations. For simplicity,
we have excluded study complexities such as investigator time, drug/
Table 1
Essential services for a centralized clinical trial unit.
Services Description
Scientiﬁc mentorship and navigation The most critical appointment for a successful CTU is to select a director who can mentor young researchers and coordinators alike.
The director must have strong leadership skills AND a research base that can be used to advise and mentor others. The ﬁrst step is in
being able to guide the idea generator in turning his/her idea into an actual and viable research protocol. The scientiﬁc mentor can
work with the novice investigator in developing his/her idea into a research study that can generate enough data to answer the
scientiﬁc question posed by the investigator. The mentor should also be aware of the navigation process within the home institution
to be able to not just discuss the research steps with the investigator, but can either guide the investigator or guide the research team
member supporting the investigator. The development and start-up of a successful research study is belabored with barriers and
pitfalls (i.e., inadequate budget, poor design, lack of power, contract negotiation, development and draft of a protocol, appropriate
data collection methods and data management). The CTU director can help guide a new investigator in avoiding, or minimizing, these
pitfalls through consultation and assistance with determining the best approach for study design as well as IRB or other institutional
approval processes. The scientiﬁc mentor can also serve as a guide to the investigator during the conduct of the clinical trial and assist
during data analysis, manuscript production, and grant submission.
Supervision and mentoring of research
staff, as needed
In today's research climate the clinical investigator is often responsible to oversee study process, manage the health care for the
study subjects/patients, and manage study staff operations (i.e., study duties, training, and time management). Most principal
investigators are given 10%–25% of their time for all of these activities making it difﬁcult to manage priorities. The CTU has in place
an operation manager/supervisor who can serve in this capacity to oversee and guide the research staff and also to assist the director
in navigating the investigator through the research regulatory process.
Protocol development/regulatory Services to assist investigators during the regulatory process for approval and activation of the research study are needed. This can
include the development of the protocol details, budgets, contracts, and IRB approval. The evolution of research regulation is such
that even experienced investigators can be troubled by budget overruns, compliance issues, and appropriate personnel oversight.
The resource of protocol development and regulatory compliance can be provided by the CTU in an ongoing basis during a before,
during and after a trial is active.
Study coordination/data management Coordinator services are an essential in order to execute IRB approved protocols and oversee the operational aspects of a clinical study
(i.e., compliance and patient recruitment). Many protocols may call for coordinator (10%–100%) for the duration of a study (a few days
to a few years). This makes hiring and maintaining adequate stafﬁng difﬁcult at best, unless research funding is continuous over long
periods of time. The CTU can provide any level of coordinating support from well-trained coordinator staff.
Innovative leading-edge programs Use of innovative leading-edge programs designed to improve clinical care at the home institution are tested and utilized in all CTU
research studies. Examples of these include an electronic protocol information center for protocol management and a research
participant tracking system that tracks study participant status and manages the informed consent and re-consenting processes.
These programs are all compliant with institutional policies and accepted and approved by funding agencies. The CTU actually
provides a testing ground for these innovative programs which are designed to improve the entire clinical research process.
272 I.T. Croghan et al. / Contemporary Clinical Trials 45 (2015) 270–276device handling, specimen collections, procedural testing, and indirect
costs, because these budgetary line items are institutionally driven.
We have also not included subject remuneration or travel
reimbursements.
3.1. Scenario #1
An investigator was approached to enroll 100 patients for a clinical
trial, which would entail 11 study visits. The amount of SC time per
patient was estimated to be 17 h. A total of 80 h for regulatory/study
start-up and 5 h per subject for data entry was anticipated. In addition,
during the study activation, the study staff was paid for the standard
paid time away (3weeks) andhad 6 holiday days paid; aswell as having
2weeks of sick time during the year, and a total of 1 week of education/
certiﬁcation and training days. The expenses are summarized in Table 3.
In this scenario, as an independent researcher the PI had to set aside
$152,075 from the study budget for coordinator resources. If thisTable 2
Success measures for a CTU.
Measure Examples
Number and skill level of clinical and basic scientists engaged in
generating new knowledge
• How many studi
• Were we able to
• Did we contribut
dollars awarded)
Levels of outcomes, safety, and service • How many quali
unit receiving fro
• How many and w
Staff's ability to deliver high value care • How many are r
clinical trials, clin
Cost efﬁciency of the conduct of research • Was the unit abl
(low cost+ high
Avoidance of costly pitfalls of research including underestimating
budgets, and non-adherence to regulatory requirements
• How many studi
Number of recruited protocol-speciﬁc participants • How many studi
Number of investigators served by the CTU, new and returning • How many new
• What was the nuinvestigator had utilized the CTU, he would have needed $115,400
from the budget and as a result could have allocatedmore of the budget
to increase his time, as well as other expert co-investigators, to the
study and patient clinical management. More importantly, the use of
the CTU would have permitted study staff to be away (sick time, vaca-
tion time, training time) with back-up study staff provided as a service.
In addition, experience has shown that hiring qualiﬁed study staff can
take an average of 4 months. In a trial with competitive enrollment,
study recruitment could be shut down before the PI could start en-
rolling, resulting in a loss of funds for the investigator.
3.2. Scenario #2
The investigator expected enrollment to be rapid. Because this trial
involved a rare condition, enrollment was slow. Many of the patients
screened did not meet the study entry criteria. The study coordinator
charged 25% effort to the study from the start of the study. Six monthses resulted in manuscripts, presentations and follow-up grants?
increase the number of publication by investigators within the Department of Medicine?
e toward an increase in the research portfolio (number of studies, amount of research
for investigators within the Department of Medicine
ty studies are we undertaking, how many protocol deviations/violations warnings is the
m the study IRB.
hat type of audits are we experiencing
etrospective chart abstracting trials, minimal risk clinical trials, above minimal risk
ical trials with pharmacotherapy, complex multisite studies, etc.?
e to recoup the cost of managing the study? (The cost to the Department
output= efﬁciently run unit))
es stayed within the estimated study cost?
es achieved enrollment goal?
investigators have we introduced to research?
mber of return clients/investigators to the unit?
Fig. 1. Resources and expertise needed for the development and success of a clinical trial unit.
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ﬁnancial review. At the meeting, she was informed that the study was
overspent by $20,000, due to the continued personnel charges, despite
having zero enrollment. As a result, the study was closed immediately,
the coordinator had to ﬁnd another position, and the investigator's
home division was asked to back-stop the overspent amount of
$20,000. The investigator was redirected to work with the CTU for con-
tinued study participation. Because the CTU is funded on a charge-out
basis, the budget proposed by the CTU has more rigor and account-
ability. The lack of patients would mean reduced charges to the study
(limited to only the time spent screening) with no charges for non-
productive time. Table 4 illustrates 3 views of this scenario: cost when
using an independent study-speciﬁc staff, cost if the CTU could not
meet recruitment target, and cost if the CTUwas successful in recruiting.
3.3. Scenario #3
An investigator is asked to enter into a milestone-based contract as
a sub-site in an NIH-based study. Milestone-based contracts are paidwhen certain enrollment and visit completion goals are met. The inves-
tigator is familiar with the disease of interest and feels that he can un-
dertake this study. Prior to taking on the study, the investigator is
guided to the CTU. The CTU suggests to the investigator that a feasibility
budget be created. Although the study is of great interest, the budget for
such a study does not appear to be too rigorous. The investigator agrees.
The resulting feasibility budget advises that the investigator will need
an additional $200K to complete the study. As a follow-up, the investi-
gator is introduced to the beneﬁts of a feasibility budget and walked
away conﬁdent in future research support by the CTU.
3.4. DOM CTU support at present time
As indicated above, the basic structure of the CTU has evolved from
that of an existing program which demonstrated a degree of success
through the conduct of a series of successful cost-effective clinical trials.
With this evolution, the core CTU staff opened its doors with the expe-
rience and knowledge already in place. As the demand for CTU services
and support continues to grow, additional staff have beenhired It can be
Fig. 2. Reporting structure and duties of the clinical trial unit staff.
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a best-in-class on-the-job-training program. The hiring process entails a
behavioral interview as well as a skills assessment. Because of this pro-
cess and the inclusion of skilled coordinators at its inception, the hiring
of additional less experienced staff has been neither difﬁcult nor bur-
densome. The growth of the unit is monitored on a weekly basis to
meet predicted demands. This monitoring takes into account the cur-
rent work load (active studies and pending requests), current stafﬁng
and predicted future demand, so that resource needs can be anticipated
and addressed in a timely manner. Downtime is rare between studies,
but when this occurs, the program absorbs the staff costs. During this
period the coordinator, who is in between studies, focuses on educa-
tional and training endeavors, as well as continuous improvement pro-
jects which beneﬁt the operations of the work unit. Risk of termination
for these skilled coordinators is very lowdue to the high demand for this
trained and experienced staff.
A description and current reporting structure of the CTU is described
in Fig. 2. In its ﬁrst 12 months, the CTU undertook 55 clinical trials,
equating to roughly 5 clinical trials per coordinator. Each new study re-
quest is evaluated for potential service by the executive committee. The
executive committee uses a series of decision criteria when considering
study intake. These criteria include availability and skill of staff as well
as investigator track record, and funding.The current CTU staff is trained on the generalities of the conduct
and regulations of clinical trials. Any study speciﬁc training is under-
taken during study training and start-up. As a result, staff has the ability
to take on any research clinical trial regardless of disease entity or study
focus. The ability to access expert opinions throughoutMayo Clinic con-
tributes to this ﬂexibility. The staff participates in regular training and is
encouraged to obtain certiﬁcation in a multitude of research focuses
which include, but are not exclusive to, wellness coaching, variety of
psychometrics, tobacco treatment specialists, spirometry, phlebotomy,
and ECG. The scientiﬁc director is an Epidemiologist with an emphasis
in study design. An active research investigator with her own studies
and interests, she also has 23 years of experience in conducting clinical
trials and is ﬂuent in all current regulatory policies. She provides men-
torship and advice both to staff and investigators with any research
related question.
4. Discussion
Successful change starts with implementation in measured steps.
A signiﬁcant factor in incorporating changes into the working culture
is acceptance by the people who are affected. The research culture
is one service that has undergone continuous improvement efforts.
This is reﬂected in the continuous revision of regulatory practices and
Table 3
Expenses related to Scenario #1.
Individual Work Unit
(100% of a coordinator
and 50% of a data entry
clerk for 1 yeara)
CTU (1780 h [86%] of a
coordinator and 500 h
[24%] of a clinical research
associate for data entry)
Cost to PI $152,075b $115,400c
Coordinator $107,520 $97,900
Per hour pay $70,720 $97,900
Beneﬁts (34%) $24,044 NA
PTO (3 weeks) $5467 NA
6 holiday days $2187 NA
7 days of sick time $2551 NA
7 days of training $2551 NA
Data entry $44,555 $17,500
Per hour pay $26,250 $17,500
Beneﬁts (34%) $8925 NA
PTO (3 weeks) $4020 NA
6 holiday days $1608 NA
7 days of sick time $1876 NA
7 days of training $1876 NA
a Please note that in amajority of instances for an independent investigator to be able to
hire a qualiﬁed coordinator or data entry clerk, a minimum of 1 year would be required
and the minimum a person would expect for a position is 50% at a minimum.
b Assuming no other time away (e.g. medical leave).
c Anymedical leave or extended time away is built in to the charge-out, back-ups in the
form of cross-training are available at all times.
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study participant and their data. Keeping in line with the “continuous
improvement” effort, the creation of the CTU was introduced as a
third step in a series of efforts designed to advance research at Mayo
Clinic. The steps taken to implement this change followed the ADKAR
model [8] and steps. We were made aware of the need for change; the
DOM at Mayo Clinic felt the desire to participate and support this
change; key stakeholders with knowledge on how to implement this
changewere identiﬁed and engaged; the same stakeholders had through
previous trials been demonstrated to possess the ability to implement
the required skills and behavior; and the current pilot trial of the CTU
is working to reinforce the sustainability of this change. Using this
approach has supported the introduction and adaptation of the DOM
CTU as a resource for research at Mayo Clinic Department of Medicine.
In the current environment where many pharmaceutical multi-site
clinical trials have competitive enrollment, sites that can start up a
study fastest, can begin enrollment earlier and therefore have a compet-
itive edge on enrollment; this translates larger budgets for high enroll-
ment sites and a net ﬁnancial loss for sites which were not able to
enroll. A research site with a well-trained coordinating staff can mobi-
lize a study toward activation and enrollment faster than a site whichTable 4




(25% of a coordinator)
CTU — enrollment






Cost to PI $43,435a $34,855b $15,315b
Coordinator $30,980 $22,400 $2860
Per hour pay $17,680 $22,400 $2860
Beneﬁts (34%) $6011 NA NA
PTO (2 weeks) $3644 NA NA




PI $12,455c $12,455c $12,455c
Per hour pay $9295 $9295 $9295
Beneﬁts (34%) $3160 $3160 $3160
a Assuming no time away (e.g. medical leave).
b Any medical leave or extended time away is built into the charge, back-ups are avail-
able at all times.
c PI calculated at current NIH rate.needs to identify, engage and train coordinators before study start-up
can even take place.
A survey of 205 research coordinators examining reasons for turn-
over revealed a need for formal training, lack of promotional opportuni-
ties, and poor allocation of workload [9,10].In an environment where
the priority is to complete all the study-related visits, issues with
study enrollment, data collection, training and workload are often not
addressed. Todate, efforts to develop a consistent infrastructure for clin-
ical trials have been limited in scope, often considering only issues of
investigator experience or patient recruitment [2]. The contribution an
experienced research staff, goodmentoring, and a track record past suc-
cesses are often downplayed, but are truly at the heart of research suc-
cess. The contribution an experienced research staff, good mentoring,
and a track record past successes are often downplayed, but are truly
at the heart of research success.
The formation of an institution-based CTU can be compared, to a
lesser degree, to the centralized CTU of the Alliance for Clinical Trials
in Oncology, which is sponsored by the National Cancer Institute. This
Alliance was formed to strengthen and streamline operations among
three NCI clinical trials cooperative group programs [11]. This group
goes beyond the integration of the statistical, data management and in-
formation technology functions for these trials by connecting clinical
trials and sponsors to investigators and sites as well as providing uni-
form training for all site personnel. When comparing thesemuch larger
programs to an institution-based central CTU we see that these large
groups have demonstrated that banding together and centralizing
world-wide study processes can result in an increased capacity to sup-
port greater trial activity and patient accrual, and also provide expertise
to respond to new approaches to trials and ever-changing regulatory
requirements [12].
The demand for building and maintaining a CTU can be a costly en-
deavor. In one estimate by Rubin, et al. [5], the annual operating budget
could range from $400,000 to $700,000. The building of the CTUatMayo
Clinicwas accomplished in a step-by-step process. In doing so, the oper-
ating budget for the actual build was minimized; one small group of
coordinators was centralized to serve a ﬁeld of study, and allowed to
expand to provide services for four divisions within a department. After
a period of time, the group was expanded to provide services to all thir-
teen divisions within the same department. In this manner, the CTUwas
built with a much more realistic budget. Initial costs were spread over a
number of years and included the anticipation of recovering most, if not
all, of these start-up costs through the fee-for-service model. The DOM
CTU infrastructure includes coordinator and supporting staff paylines,
as well as unit supplies that are not study-speciﬁc and are general to
the CTU operations (such as computers). These CTU operational costs
are the basis for the development of the CTU charge out model. The
Department of Medicine sponsored this activity and made the initial
ﬁnancial investment as proof of concept, however once established,
the majority of ongoing ﬁnancial support will be received through the
charge-outmodel, any fall-out is covered by theDepartment ofMedicine.
Due to the high demand for the CTU staff, this cost has been minimized
and in many instances eliminated.
The beneﬁts of utilizing a CTU include access to highly-trained study
staff for which the investigators do not have administrative responsi-
bility (i.e. - personnel issues); investigators paying only for the time
the staff engages on their speciﬁc study; access to various levels of sup-
port staff for the duration of the study, without having to limit the
coordinators' time away; and investigators having access to research
expertise, as needed. Access to experienced research investigators
who have knowledge of clinical trial conduct has immeasurable value
to inexperienced research investigators. The experienced researchers
can serve as a mentors or co-investigators who understand the many
facets of research. These experienced investigators can communicate
with the study team (investigators and staff alike) to discuss research
ideas and strategies. It is through such collaboration that concepts are
deliberated and successful studies are designed. To have someone of
276 I.T. Croghan et al. / Contemporary Clinical Trials 45 (2015) 270–276this caliber available at all times to investigators is one of the greatest
beneﬁts of a centralized CTU.
Challenges to the development of a centralized fee-for-service
model exist. The ﬁrst challenge is the payment structure. Costs for this
service must be balanced to allow the unit to recover most of the infra-
structure expenses, but not so high that they become a barrier for the
investigator. Leadership must ensure that CTUs are not designed to
generate a proﬁt but rather cover costs while providing a service to
institutional investigators. The second challenge is the effort it takes
to maintain the availability of well-trained coordinators for service
requests that may require long-term commitments. To address this
issue, the studies are contracted out on a yearly basis and evaluated
for renewal. The third challenge occurs when demand for services is
greater than the capacity of the unit. In order to maintain the cost-
efﬁciency of the model, resources have to meet the demand most of
the time. When demand for CTU services exceeds capacity, studies
should be prioritized. When capacity exceeds demand, the operational
costs of the CTU will need to be covered by the institution. Building
an institutional CTU in a step-wise manner allows resources to grow
over time with increasing demand. As demand grows, and the reputa-
tion of the CTU strengthens, sustainability of this valuable resource
is achieved.
In an era of constrained resources for medical research, declining
paylines at the NIH, and the defunding of historically federally-funded
clinical research units, academic institutions need to develop innovative
models to support their core mission of advancing clinical research. The
Mayo Clinic DOM CTU serves as a model for how organizations can
leverage existing resources to advance this mission.
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